MA33428B1 - Agonistes du gpr119 - Google Patents

Agonistes du gpr119

Info

Publication number
MA33428B1
MA33428B1 MA34531A MA34531A MA33428B1 MA 33428 B1 MA33428 B1 MA 33428B1 MA 34531 A MA34531 A MA 34531A MA 34531 A MA34531 A MA 34531A MA 33428 B1 MA33428 B1 MA 33428B1
Authority
MA
Morocco
Prior art keywords
gpr119
inducers
obesity
diabetes
formula
Prior art date
Application number
MA34531A
Other languages
Arabic (ar)
English (en)
Inventor
David Gene Barrett
Melendo Ana Belen Bueno
Jeffry Bernard Franciskovich
Bin Liu
Kumiko Takeuchi
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43449712&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA33428(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of MA33428B1 publication Critical patent/MA33428B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

Composés agonistes du GPR119 de formule : (I) et compositions pharmaceutiques destinés au traitement du diabète et de l'obésité.
MA34531A 2009-07-15 2010-07-12 Agonistes du gpr119 MA33428B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP09382114 2009-07-15
US24544509P 2009-09-24 2009-09-24
PCT/US2010/041645 WO2011008663A1 (fr) 2009-07-15 2010-07-12 Agonistes du gpr119

Publications (1)

Publication Number Publication Date
MA33428B1 true MA33428B1 (fr) 2012-07-03

Family

ID=43449712

Family Applications (1)

Application Number Title Priority Date Filing Date
MA34531A MA33428B1 (fr) 2009-07-15 2010-07-12 Agonistes du gpr119

Country Status (24)

Country Link
US (1) US8207344B2 (fr)
EP (1) EP2454251A1 (fr)
JP (1) JP5715127B2 (fr)
KR (1) KR101365854B1 (fr)
CN (1) CN102471313B (fr)
AR (1) AR077638A1 (fr)
AU (1) AU2010273642B2 (fr)
BR (1) BRPI1015921A2 (fr)
CA (1) CA2764906C (fr)
CO (1) CO6480977A2 (fr)
CR (1) CR20120012A (fr)
DO (1) DOP2012000006A (fr)
EA (1) EA020540B1 (fr)
EC (1) ECSP12011606A (fr)
IL (1) IL216776A0 (fr)
MA (1) MA33428B1 (fr)
MX (1) MX2012000704A (fr)
NZ (1) NZ597125A (fr)
PE (1) PE20121045A1 (fr)
SG (1) SG177646A1 (fr)
TN (1) TN2012000002A1 (fr)
TW (1) TWI429634B (fr)
WO (1) WO2011008663A1 (fr)
ZA (1) ZA201200227B (fr)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA05007485A (es) 2003-01-14 2006-01-30 Arena Pharm Inc Derivados de arilo y heteroarilo 1,2,3-trisubstituidos como moduladores del metabolismo y la profilaxis y tratamiento de trastornos relacionados con ello tales como diabetes e hiperglicemia.
EP2108960A1 (fr) 2008-04-07 2009-10-14 Arena Pharmaceuticals, Inc. Procédés d'utilisation d'un récepteur couplé à protéine G pour identifier les secrétagogues de peptide YY (PYY) et composés utiles dans le traitement des conditions modulées de secrétagogues BY (PYY) et composés utiles dans le traitement des conditions par PYY
EP2547339A1 (fr) 2010-03-18 2013-01-23 Boehringer Ingelheim International GmbH Combinaisons d'agonistes de gpr119 et d'inhibiteurs de dpp-iv, linagliptine, pour le traitement du diabète et d'états apparentés
EP3323818A1 (fr) 2010-09-22 2018-05-23 Arena Pharmaceuticals, Inc. Modulateurs du récepteur gpr119 et traitement de troubles associés
US20140018371A1 (en) * 2011-04-01 2014-01-16 Arena Pharmaceuticals, Inc. Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto
US8957062B2 (en) 2011-04-08 2015-02-17 Merck Sharp & Dohme Corp. Substituted cyclopropyl compounds, compositions containing such compounds and methods of treatment
WO2012170702A1 (fr) * 2011-06-08 2012-12-13 Arena Pharmaceuticals, Inc. Modulateurs du récepteur gpr119 et traitement de troubles associés à celui-ci
CA2836487A1 (fr) 2011-06-09 2012-12-13 Rhizen Pharmaceuticals Sa Nouveaux composes utilises comme modulateurs de gpr-119
EP2720544B1 (fr) 2011-06-16 2016-12-21 Merck Sharp & Dohme Corp. Composés cyclopropylés substitués, compositions contenant de tels composés et procédés de traitement
EP2760855B1 (fr) 2011-09-30 2017-03-15 Merck Sharp & Dohme Corp. Composés de cyclopropyle substitués, compositions contenant ces composés ainsi que leur utilisation pour le traitement du diabète de type 2
WO2013062835A1 (fr) * 2011-10-24 2013-05-02 Merck Sharp & Dohme Corp. Composés de pipéridinyle substitués utiles comme agonistes du récepteur gpr119
EP2771000B1 (fr) 2011-10-24 2016-05-04 Merck Sharp & Dohme Corp. Composés de pipéridinyle substitués utilisés comme agonistes du récepteur gpr119
WO2013074388A1 (fr) 2011-11-15 2013-05-23 Merck Sharp & Dohme Corp. Composés de cyclopropyle substitués utiles à titre d'agonistes de gpr119
DK2858986T3 (da) * 2012-06-12 2019-11-25 Chong Kun Dang Pharmaceutical Corp Piperidinderivater som gpr119-agonister
HK1210825A1 (en) 2012-07-11 2016-05-06 Elcelyx Therapeutics, Inc. Compositions comprising statins, biguanides and further agents for reducing cardiometabolic risk
WO2014052619A1 (fr) * 2012-09-27 2014-04-03 Irm Llc Dérivés et compositions de pipéridine comme modulateurs de l'activité de gpr119
CN110028494A (zh) 2013-11-26 2019-07-19 株式会社钟根堂 酰胺衍生物、其立体异构体或其药学上可接受的盐及包含其的药物组合物
KR101651505B1 (ko) * 2014-05-02 2016-08-29 현대약품 주식회사 싸이클로 헥센 유도체, 이의 제조방법 및 이를 유효성분으로 함유하는 대사성 질환의 예방 또는 치료용 약학적 조성물
PL3242666T3 (pl) 2015-01-06 2025-02-17 Arena Pharmaceuticals, Inc. Związek do zastosowania w leczeniu dolegliwości związanych z receptorem s1p1
BR112017027656B1 (pt) 2015-06-22 2023-12-05 Arena Pharmaceuticals, Inc. Hábito cristalino de placa livre de sal de l-arginina de ácido (r)-2-(7-(4- ciclopentil-3-(trifluorometil)benzilóxi)- 1,2,3,4-tetra-hidrociclo-penta[b]indol-3- il)acético, composição farmacêutica que o compreende, seus usos e método de preparação do mesmo
MX2019009841A (es) 2017-02-16 2020-01-30 Arena Pharm Inc Compuestos y metodos para el tratamiento de la colangitis biliar primaria.
CA3102136A1 (fr) 2018-06-06 2019-12-12 Arena Pharmaceuticals, Inc. Methodes de traitement de troubles associes au recepteur s1p1<sb />
TW202140440A (zh) 2020-02-28 2021-11-01 美商克力歐普股份有限公司 Gpr40激動劑
WO2021236617A1 (fr) 2020-05-19 2021-11-25 Kallyope, Inc. Activateurs d'ampk
CN116390925A (zh) 2020-06-26 2023-07-04 卡尔优普公司 Ampk活化剂

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA05007485A (es) * 2003-01-14 2006-01-30 Arena Pharm Inc Derivados de arilo y heteroarilo 1,2,3-trisubstituidos como moduladores del metabolismo y la profilaxis y tratamiento de trastornos relacionados con ello tales como diabetes e hiperglicemia.
WO2008025799A1 (fr) * 2006-08-30 2008-03-06 Biovitrum Ab (Publ) Composés de pyridazine permettant de traiter les troubles liés à gpr119
US7638541B2 (en) * 2006-12-28 2009-12-29 Metabolex Inc. 5-ethyl-2-{4-[4-(4-tetrazol-1-yl-phenoxymethyl)-thiazol-2-yl]-piperidin-1-yl}-pyrimidine
BRPI0817211A2 (pt) * 2007-09-20 2017-05-16 Irm Llc composto composições como moduladores da atividade de gpr119

Also Published As

Publication number Publication date
TWI429634B (zh) 2014-03-11
ECSP12011606A (es) 2012-02-29
CA2764906C (fr) 2014-06-10
WO2011008663A1 (fr) 2011-01-20
CO6480977A2 (es) 2012-07-16
JP5715127B2 (ja) 2015-05-07
PE20121045A1 (es) 2012-08-09
KR101365854B1 (ko) 2014-02-21
KR20120024964A (ko) 2012-03-14
MX2012000704A (es) 2012-03-07
CR20120012A (es) 2012-03-28
EA201270169A1 (ru) 2012-06-29
AU2010273642A1 (en) 2012-01-19
IL216776A0 (en) 2012-03-01
SG177646A1 (en) 2012-02-28
NZ597125A (en) 2013-08-30
CA2764906A1 (fr) 2011-01-20
DOP2012000006A (es) 2012-01-31
ZA201200227B (en) 2013-06-26
JP2012533546A (ja) 2012-12-27
US20110015199A1 (en) 2011-01-20
EP2454251A1 (fr) 2012-05-23
AU2010273642B2 (en) 2014-03-13
US8207344B2 (en) 2012-06-26
CN102471313B (zh) 2014-06-04
TW201114757A (en) 2011-05-01
AR077638A1 (es) 2011-09-14
TN2012000002A1 (en) 2013-09-19
BRPI1015921A2 (pt) 2016-04-26
CN102471313A (zh) 2012-05-23
EA020540B1 (ru) 2014-11-28

Similar Documents

Publication Publication Date Title
MA33428B1 (fr) Agonistes du gpr119
GEP20146102B (en) Compounds and compositions as protein kinase inhibitors
EA201170151A1 (ru) Пиперидиниловые агонисты gpcr
GEP20135983B (en) 1-benzyl-3-hydroxymethylindazole derivatives and usage therein treatment of diseases based on mcp-1, cx3cr1 and p40 expression
EA201200918A1 (ru) Производные пирролидин карбоновой кислоты как агонисты сопряженного с g-белком рецептора 43 (gpr43), фармацевтическая композиция и методы их использования при лечении метаболических нарушений
MX2010005861A (es) Agonistas novedosos de los receptores de glucocorticoides.
MA32904B1 (fr) Composes de purine
MX2011006006A (es) Compuestos, composicion farmaceutica y metodos para utilizarse en el tratamiento de trastornos metabolicos.
DE602007009420D1 (de) Oxadiazolderivate als s1p1-rezeptor-agonisten
MX2009008159A (es) Compuestos y composiciones como moduladores de la actividad de gpr119.
GEP20146125B (en) Aminopyrimidines as syk inhibitors
MA31084B1 (fr) Derives de piperidine agonistes de gpcr
EA201100007A1 (ru) Производные хиноксалиндиона
EA200870216A1 (ru) Амидо соединения и их применение в качестве лекарственных средств
EA201100503A1 (ru) Глюкозидные производные и их применения
MX2012002366A (es) Agonistas novedosos de receptores beta 3 andrenergicos derivados de pirrolidina.
EA201190207A1 (ru) Соединения для лечения метаболических расстройств
ATE524450T1 (de) 5-phenyl-isoxazol-3-carboxamid-derivate als trpv1-modulatoren
EA200970065A1 (ru) Производные пиперазинила, предназначенные для лечения заболеваний, опосредованных рецептором gpr38
MA33242B1 (fr) Composes pour le traitement de troubles metaboliques
EA201070327A1 (ru) Катехоламиновые производные и их пролекарства
UA112055C2 (uk) Солі 4-[2-[[5-метил-1-(2-нафталініл)-1h-піразол-3-іл]оксі]етил]морфоліну
CY1117705T1 (el) Νεες ενωσεις διυποκατεστημενης 3,4-διαμινο-3-κυκλοβουτενο-διονης-1,2 για χρηση στην θεραπεια προκαλουμενων απο χημειοκινη ασθενειων
GEP20135913B (en) 1-benzyl-3-hydroxymethylindazole derivatives and use thereat treatment of diseases based on mcp-1 and cx3cr1 expression
MX2011012669A (es) Nuevos agonistas del receptor de glucocorticoides.